Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 29 min ago
Peer-reviewedCC BY 4.0Antimicrobial Agents and Chemotherapy

In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022

  • Sarah M. McLeod1
  • Samir H. Moussa1
  • Meredith Hackel2
  • Carmen Au3
  • Pierre Daram3
  1. 1Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., Waltham, Massachusetts, USA
  2. 2IHMA, Inc., Schaumburg, Illinois, USA
  3. 3Global Antibiotic R&D Partnership, Geneva, Switzerland
Read full textPDFDOICite

Abstract

Zoliflodacin is a first-in-class spiropyrimidinetrione, oral, single-dose antibacterial recently approved by the US FDA for treatment of uncomplicated urogenital gonorrhea. Isolates of Neisseria gonorrhoeae (n = 322) collected in the United States in 2020–2022 by the Centers for Disease Control and Prevention, as well as two ceftriaxone-resistant isolates, were tested for susceptibility to zoliflodacin. All isolates were susceptible to zoliflodacin with MIC50/90 values of 0.12 µg/mL. Zoliflodacin activity was consistent over time and against ceftriaxone-, ciprofloxacin-, and tetracycline-resistant and azithromycin-non-susceptible isolates.

Related

  1. In vitro activity of gepotidacin against baseline Neisseria gonorrhoeae phenotypes and genotypes recovered from a clinical trial for uncomplicated urogenital gonorrhea (EAGLE-1)
    Charles Jakielaszek, William Flight, Dan Lythgoe +2
    Antimicrobial Agents and ChemotherapyPeer-reviewedCC BY 4.0Full textMicrobiologyPMC
  2. Mucosal ACP subunit vaccine formulated with a small molecule STING agonist drives protective TH1/TH17 responses and serum bactericidal antibodies against Neisseria gonorrhoeae
    A. Chanda, I. A. Cadena, J. Nazir +8
    bioRxivPreprintCC BYFull textMicrobiologybioRxiv
  3. Pathogenicity and virulence of Neisseria gonorrhoeae
    Michael M. Girgis, Myron Christodoulides
    VirulencePeer-reviewedCC BY 4.0Full textMicrobiologyPMC
  4. The global epidemiology of antibiotic-resistant Neisseria gonorrhoeae
    Matthew Ho, Paul C Adamson, Jeffrey D Klausner +1
    JAC-antimicrobial resistancePeer-reviewedCC BYFull textMicrobiologyEurope PMCPMC
  5. One-pot LAMP-CRISPR/Cas12b coupled with nanoparticle-based biosensor for point-of-care test of Neisseria gonorrhoeae
    Ling Xie, Yan Tan, Yanyan Qin +4
    BMC MicrobiologyPeer-reviewedCC BYFull textMicrobiologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{mcleod2026vitro,
  title = {{In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022}},
  author = {Sarah M. McLeod and Samir H. Moussa and Meredith Hackel and Carmen Au and Pierre Daram},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  month = aug,
  doi = {10.1128/aac.00527-26},
  url = {https://doi.org/10.1128/aac.00527-26},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022
AU  - Sarah M. McLeod
AU  - Samir H. Moussa
AU  - Meredith Hackel
AU  - Carmen Au
AU  - Pierre Daram
PY  - 2026
DA  - 2026/08/03
JO  - Antimicrobial Agents and Chemotherapy
DO  - 10.1128/aac.00527-26
UR  - https://doi.org/10.1128/aac.00527-26
AB  - Zoliflodacin is a first-in-class spiropyrimidinetrione, oral, single-dose antibacterial recently approved by the US FDA for treatment of uncomplicated urogenital gonorrhea. Isolates of Neisseria gonorrhoeae (n = 322) collected in the United States in 2020–2022 by the Centers for Disease Control and Prevention, as well as two ceftriaxone-resistant isolates, were tested for susceptibility to zoliflodacin. All isolates were susceptible to zoliflodacin with MIC50/90 values of 0.12 µg/mL. Zoliflodacin activity was consistent over time and against ceftriaxone-, ciprofloxacin-, and tetracycline-resistant and azithromycin-non-susceptible isolates.
SN  - 0066-4804
SN  - 1098-6596
ER  -